Plasma l-carnitine and risks of cardiovascular events and recurrent stroke after ischemic stroke: A nested case-control study

Du, Jigang; Miao, Mengyuan; Lu, Zian; Chen, Haichang; Bao, Anran; Che, Bizhong; Zhang, Jintao; Ju, Zhong; Xu, Tan; He, Jiang; Zhang, Yonghong; Zhong, Chongke

doi:10.1016/j.numecd.2022.08.016

Cited by 2 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on the above analysis, the screened key features were identified according to the human metabolome database (HMDB), and the promising biomarkers were assigned to metabolites in Table S8 (Supporting Information). In Figure 5g, the l-carnitine (m/z 162.11, HMDB0000062) and taurine (m/z 147.926, HMDB0000251) presented up-regulated in UA compared with CON that is consistent with previous studies that higher l-carnitine has recognized to be relevant to cardiovascular disease [42] and widely discovered as the biomarkers for the diagnosis of AMI and the risk stratification of ACS. [43] Moreover, studies have suggested that taurine may have neuro-and cardioprotective functions, and the upregulated taurine in UA may be relevant to the neurological outcomes.…”

Section: Serum Metabolic Profiling For Early Diagnosis and Risk Strat...supporting

confidence: 88%

Hollow Crystallization COF Capsuled MOF Hybrids Depict Serum Metabolic Profiling for Precise Early Diagnosis and Risk Stratification of Acute Coronary Syndrome

Yang

Pan

et al. 2023

Advanced Science

View full text Add to dashboard Cite

Acute coronary syndrome (ACS), comprising unstable angina (UA) and acute myocardial infarction (AMI), is the leading cause of death worldwide. Currently, lacking effective strategies for classifying ACS hinders the prognosis improvement of ACS patients. Disclosing the nature of metabolic disorders holds the potential to reflect disease progress and high‐throughput mass spectrometry‐based metabolic analysis is a promising tool for large‐scale screening. Herein, a hollow crystallization COF capsuled MOF hybrids (UiO‐66@HCOF) assisted serum metabolic analysis is developed for the early diagnosis and risk stratification of ACS. UiO‐66@HCOF exhibits unrivaled chemical and structural stability as well as endowing satisfying desorption/ionization efficiency in the detection of metabolites. Paired with machine learning algorithms, early diagnosis of ACS is achieved with the area under the curve (AUC) value of 0.945 for validation sets. Besides, a comprehensive ACS risk stratification method is established, and the AUC value for the discrimination of ACS from healthy controls, and AMI from UA are 0.890, and 0.928. Moreover, the AUC value of the subtyping of AMI is 0.964. Finally, the potential biomarkers exhibit high sensitivity and specificity. This study makes metabolic molecular diagnosis a reality and provided new insight into the progress of ACS.

show abstract

Section: Serum Metabolic Profiling For Early Diagnosis and Risk Strat...supporting

confidence: 88%

Hollow Crystallization COF Capsuled MOF Hybrids Depict Serum Metabolic Profiling for Precise Early Diagnosis and Risk Stratification of Acute Coronary Syndrome

Yang

Pan

et al. 2023

Advanced Science

View full text Add to dashboard Cite

show abstract

“…The portal circulation carries TMA to the liver, where it is quickly changed into Trimethylamine-N-oxide (TMAO) by host hepatic flavin monooxygenases. According to clinical investigations, there is a link between a higher plasma TMAO level and a higher chance of having serious adverse cardiovascular events (23)(24)(25)(26). Some studies show a link between TAMO and steatosis promotion and NAFLD progression (28).…”

Section: сажетакmentioning

confidence: 99%

The effects of L-carnitine in reducing hepatotoxicity of statins in rats

Ibrahim,

Bader,

Bader

2023

Medicinski časopis

View full text Add to dashboard Cite

Objective. The first line of treatment for hyperlipidemia is statins. In this group, atorvastatin is the most popular and effective drug. Hepatic toxicity and myopathy are the two observed adverse effects of statins. The active form of carnitine is L-carnitine, a water-soluble compound found in food, the body, and the majority of dietary supplements. There are many uses for L-carnitine in the human body. It assists in the removal of free radicals from the body and lowers hydrogen peroxide production, both of which may guard against liver side effects brought on by statins. Methods. Eighty rats were randomly divided into four main groups: control, L-carnitine, atorvastatin, and combination (L-carnitine + atorvastatin) groups. These groups were subdivided into three subgroups based on different doses of the drugs. The L-carnitine group was divided into L200, L300, and L400. The atorvastatin group was divided into A10, A15, and A20. The combination group was subdivided into AL10/200, AL15/300, and AL20/400. All groups received their treatments daily for one month. Results. According to our findings, the effects of L-carnitine (200 mg/kg daily) on the increase in AST brought on by atorvastatin are not statistically significant, although they are significant on the increases in ALT, ALP and TSB. L-carnitine still has substantial impacts on ALT, ALP and TSB even at larger doses, while its impacts on AST levels had become significant. Conclusion. Our research highlights the beneficial effects of supplementing with L-carnitine over a four-week period, which effectively mitigates the liver damage caused by atorvastatin.

show abstract

Plasma l-carnitine and risks of cardiovascular events and recurrent stroke after ischemic stroke: A nested case-control study

Cited by 2 publications

References 30 publications

Hollow Crystallization COF Capsuled MOF Hybrids Depict Serum Metabolic Profiling for Precise Early Diagnosis and Risk Stratification of Acute Coronary Syndrome

Hollow Crystallization COF Capsuled MOF Hybrids Depict Serum Metabolic Profiling for Precise Early Diagnosis and Risk Stratification of Acute Coronary Syndrome

The effects of L-carnitine in reducing hepatotoxicity of statins in rats

Contact Info

Product

Resources

About